• Robin T Zon, James N Frame, Michael N Neuss, Ray D Page, Dana S Wollins, Steven Stranne, and Linda D Bosserman.
• Michiana Hematology-Oncology PC, South Bend, IN Charleston Area Medical Center, Charleston, WV; Vanderbilt-Ingram Cancer Center, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; American Society of Clinical Oncology, Alexandria, VA; Polsinelli Shughart, Washington, DC; and City of Hope, Rancho Cucamonga, CA docrzon@aol.com.
• J Oncol Pract. 2016 Mar 1; 12 (3): 261-6.

AbstractThe use of clinical pathways in oncology care is increasingly important to patients and oncology providers as a tool for enhancing both quality and value. However, with increasing adoption of pathways into oncology practice, concerns have been raised by ASCO members and other stakeholders. These include the process being used for pathway development, the administrative burdens on oncology practices of reporting on pathway adherence, and understanding the true impact of pathway use on patient health outcomes. To address these concerns, ASCO's Board of Directors established a Task Force on Clinical Pathways, charged with articulating a set of recommendations to improve the development of oncology pathways and processes, allowing the demonstration of pathway concordance in a manner that promotes evidence-based, high-value care respecting input from patients, payers, and providers. These recommendations have been approved and adopted by ASCO's Board of Directors on August 12, 2015, and are presented herein.Copyright © 2016 by American Society of Clinical Oncology.

12 keywords...

hide…